B+
Bull case
30%
Probability
Target price
$135.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
CELC
CelcuityANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
FDA approval, a preferred Category 1 NCCN recommendation, positive Phase 3 mutant-cohort results and an imminent launch create multiple paths for gedatolisib to expand across second- and potentially first-line HR+/HER2- advanced breast cancer. [#SEC-8K-2026-08-13]
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +13.0.
What can break
A former 10% owner disclosed approximately 3.10 million shares of open-market sales at $102.50, which may weigh on sentiment but does not indicate operating performance. [#SEC-FORM4-2026-07-16]
Momentum
12
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $102.00 · Bull $135.00 · Bear $55.00Analysis 2026-09-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $161.09
Why
Momentum12 · Δ7d -16.3
Value41 · Δ7d -0.0
Sentiment100 · Δ7d +13.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +13.0.
Contradictions & invalidation
- • A former 10% owner disclosed approximately 3.10 million shares of open-market sales at $102.50, which may weigh on sentiment but does not indicate operating performance. [#SEC-FORM4-2026-07-16]
- • Commercial uptake, physician adoption, reimbursement and launch execution for REVTORPYK remain unproven.
- • The valuation now depends on a first commercial launch and continued regulatory execution around a concentrated lead asset.
Catalyst clock
2026-09-30
PIK3CA-mutant supplemental NDA submission
Lead driver: Sentiment · See AI snapshot
Momentum
12
9% active weight
Current posture
7d trendSoftening
Δ7d
-16.3
Δ21d
+3.0
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
100
62% active weight
Current posture
7d trendImproving
Δ7d
+13.0
Δ21d
+3.7
Why this grade
Composite grade A. Momentum 12.4 / Value 41.2 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-11. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$102.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$55.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$4.52B
Beta
0.37
Shares Out
48.93M
P/E (TTM) · Derived
-24.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-25.23
Rev YoY
-
EPS YoY
+38.8%
Gross Margin
-
Op Margin
-
Net Debt
-$119.59M
Current Ratio
8.93
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data